Spontaneous sustained ventricular tachyarrhythmias during treatment with type IA antiarrhythmic agents

Peter J. Kudenchuk, Jack Kron, Charles Walance, John H. McAnulty

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Twenty-six patients who developed their first clinical episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) while taking type IA antiarrhythmic agents for more benign rhythm disturbances were rechallenged with the identical drug during electrophysiologic testing. Patients with these new drug-associated spontaneous ventricular arrhythmias often manifested a preexisting substrate for such arrhythmias: sustained VT or VF was induced in 65% of patients at baseline, and in 58% of patients when tested with their previously taken antiarrhythmic drug. Among those without inducible sustained ventricular arrhythmias in the drug-free state, 78% remained free of inducible sustained arrhythmias when tested with the same drug they had been taking at the time of the clinical arrhythmia. Even patients without a definable electrophysiologic substrate for sustained VT or VF remained at risk for arrhythmia recurrence if treated with alternative antiarrhythmic medications: 40% of such patients who continued to receive an antiarrhythmic agent different from that being administered when their clinical VT or VF occurred had recurrent spontaneous ventricular tachyarrhythmias during follow-up. Thus, patients with drug-associated clinical sustained ventricular tachycardias form a heterogenous group that should be evaluated individually and not empirically managed for a "proarrhythmic effect" simply by antiarrhythmic drug withdrawal or drug substitution.

Original languageEnglish (US)
Pages (from-to)446-452
Number of pages7
JournalThe American Journal of Cardiology
Volume65
Issue number7
DOIs
StatePublished - Feb 15 1990

Fingerprint

Tachycardia
Ventricular Tachycardia
Cardiac Arrhythmias
Ventricular Fibrillation
Pharmaceutical Preparations
Anti-Arrhythmia Agents
Therapeutics
Drug Substitution
Recurrence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Spontaneous sustained ventricular tachyarrhythmias during treatment with type IA antiarrhythmic agents. / Kudenchuk, Peter J.; Kron, Jack; Walance, Charles; McAnulty, John H.

In: The American Journal of Cardiology, Vol. 65, No. 7, 15.02.1990, p. 446-452.

Research output: Contribution to journalArticle

Kudenchuk, Peter J. ; Kron, Jack ; Walance, Charles ; McAnulty, John H. / Spontaneous sustained ventricular tachyarrhythmias during treatment with type IA antiarrhythmic agents. In: The American Journal of Cardiology. 1990 ; Vol. 65, No. 7. pp. 446-452.
@article{bbafcc7ee4dd49a8b0bd72e28cbc51e2,
title = "Spontaneous sustained ventricular tachyarrhythmias during treatment with type IA antiarrhythmic agents",
abstract = "Twenty-six patients who developed their first clinical episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) while taking type IA antiarrhythmic agents for more benign rhythm disturbances were rechallenged with the identical drug during electrophysiologic testing. Patients with these new drug-associated spontaneous ventricular arrhythmias often manifested a preexisting substrate for such arrhythmias: sustained VT or VF was induced in 65{\%} of patients at baseline, and in 58{\%} of patients when tested with their previously taken antiarrhythmic drug. Among those without inducible sustained ventricular arrhythmias in the drug-free state, 78{\%} remained free of inducible sustained arrhythmias when tested with the same drug they had been taking at the time of the clinical arrhythmia. Even patients without a definable electrophysiologic substrate for sustained VT or VF remained at risk for arrhythmia recurrence if treated with alternative antiarrhythmic medications: 40{\%} of such patients who continued to receive an antiarrhythmic agent different from that being administered when their clinical VT or VF occurred had recurrent spontaneous ventricular tachyarrhythmias during follow-up. Thus, patients with drug-associated clinical sustained ventricular tachycardias form a heterogenous group that should be evaluated individually and not empirically managed for a {"}proarrhythmic effect{"} simply by antiarrhythmic drug withdrawal or drug substitution.",
author = "Kudenchuk, {Peter J.} and Jack Kron and Charles Walance and McAnulty, {John H.}",
year = "1990",
month = "2",
day = "15",
doi = "10.1016/0002-9149(90)90808-E",
language = "English (US)",
volume = "65",
pages = "446--452",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Spontaneous sustained ventricular tachyarrhythmias during treatment with type IA antiarrhythmic agents

AU - Kudenchuk, Peter J.

AU - Kron, Jack

AU - Walance, Charles

AU - McAnulty, John H.

PY - 1990/2/15

Y1 - 1990/2/15

N2 - Twenty-six patients who developed their first clinical episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) while taking type IA antiarrhythmic agents for more benign rhythm disturbances were rechallenged with the identical drug during electrophysiologic testing. Patients with these new drug-associated spontaneous ventricular arrhythmias often manifested a preexisting substrate for such arrhythmias: sustained VT or VF was induced in 65% of patients at baseline, and in 58% of patients when tested with their previously taken antiarrhythmic drug. Among those without inducible sustained ventricular arrhythmias in the drug-free state, 78% remained free of inducible sustained arrhythmias when tested with the same drug they had been taking at the time of the clinical arrhythmia. Even patients without a definable electrophysiologic substrate for sustained VT or VF remained at risk for arrhythmia recurrence if treated with alternative antiarrhythmic medications: 40% of such patients who continued to receive an antiarrhythmic agent different from that being administered when their clinical VT or VF occurred had recurrent spontaneous ventricular tachyarrhythmias during follow-up. Thus, patients with drug-associated clinical sustained ventricular tachycardias form a heterogenous group that should be evaluated individually and not empirically managed for a "proarrhythmic effect" simply by antiarrhythmic drug withdrawal or drug substitution.

AB - Twenty-six patients who developed their first clinical episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) while taking type IA antiarrhythmic agents for more benign rhythm disturbances were rechallenged with the identical drug during electrophysiologic testing. Patients with these new drug-associated spontaneous ventricular arrhythmias often manifested a preexisting substrate for such arrhythmias: sustained VT or VF was induced in 65% of patients at baseline, and in 58% of patients when tested with their previously taken antiarrhythmic drug. Among those without inducible sustained ventricular arrhythmias in the drug-free state, 78% remained free of inducible sustained arrhythmias when tested with the same drug they had been taking at the time of the clinical arrhythmia. Even patients without a definable electrophysiologic substrate for sustained VT or VF remained at risk for arrhythmia recurrence if treated with alternative antiarrhythmic medications: 40% of such patients who continued to receive an antiarrhythmic agent different from that being administered when their clinical VT or VF occurred had recurrent spontaneous ventricular tachyarrhythmias during follow-up. Thus, patients with drug-associated clinical sustained ventricular tachycardias form a heterogenous group that should be evaluated individually and not empirically managed for a "proarrhythmic effect" simply by antiarrhythmic drug withdrawal or drug substitution.

UR - http://www.scopus.com/inward/record.url?scp=0025101217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025101217&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(90)90808-E

DO - 10.1016/0002-9149(90)90808-E

M3 - Article

C2 - 2305683

AN - SCOPUS:0025101217

VL - 65

SP - 446

EP - 452

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -